---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-224065"
form_type: "8-K"
ticker: "STRO"
cik: "0001382101"
company_name: "SUTRO BIOPHARMA, INC."
filed_at: "2026-05-14T20:15:18+00:00"
generated_at: "2026-05-14T20:52:59.263924+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Sutro Q1 cash $202.6M; revenue $14.5M; luvelta closed; STRO-004 data mid-2026

## Summary
- Cash $202.6M as of Mar 31, 2026 (vs $141.4M Dec 2025); $110M stock offering extends runway into Q2 2028.
- Q1 revenue $14.5M (down from $17.4M YoY); total R&D+G&A $44.1M (down from $64.9M YoY).
- STRO-004 Phase 1 dose-escalation ongoing; initial safety, PK, activity data expected mid-2026.
- Astellas collaboration: first TROP2 dual-payload iADC in clinic; $10M milestone received April 2026.
- Luvelta program closed; no further investment or business development efforts.

## SEC filing metadata
- accession: 0001193125-26-224065
- form_type: 8-K
- ticker: STRO
- cik: 0001382101
- company_name: SUTRO BIOPHARMA, INC.
- filed_at: 2026-05-14T20:15:18+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1382101/000119312526224065/0001193125-26-224065-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1382101/000119312526224065/stro-20260514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-224065
- JSON: https://secwatch.observer/filing/0001193125-26-224065.json
- Plain text: https://secwatch.observer/filing/0001193125-26-224065.txt

## Key facts
- Earnings Releases
  SUTRO BIOPHARMA, INC. reported financial results for the first quarter of 2026.
  - Period: the first quarter of 2026
  - Result: reported results
  source text: Sutro Biopharma, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1382101/000119312526224065/0001193125-26-224065-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.